The main purpose of this trial is to find out whether BHB-1893 works better than metoprolol in adults with symptoms of obstructive hypertrophic cardiomyopathy (oHCM). The trial includes adults who are currently being treated for oHCM or who have not yet been treated.
Eligibility
Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Key Inclusion Criteria:
* Diagnosed with oHCM per the protocol specified criteria
* NYHA Class II or III at screening visits
* KCCQ-CSS that meets the protocol specified criteria at screening visits
* Adequate acoustic windows for echocardiography
Key Exclusion Criteria:
* Medical indication for either β-blocker or calcium-channel blocker therapy, other than oHCM, prohibiting drug discontinuation
* History of intolerance or medical contraindication to β-blocker therapy
* Resting systolic blood pressure (SBP) of \>160 millimeters of mercury (mmHg) at screening visits
* Resting heart rate of \>100 beats per minute (bpm) at screening visits
* Significant valvular heart disease, defined as:
* Moderate to severe valvular aortic stenosis or fixed subaortic obstruction;
* Mitral regurgitation not due to systolic anterior motion of the mitral valve (per Investigator's judgment)
Other protocol-defined criteria apply.
Primary outcome measure(s)
Change from Baseline in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET) — Baseline, Week 24
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
